Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Kadimastem In the News
July 20th, 2021
Global Business Leaders Magazine publishes Kadimastem in Top 10 Companies to Know in 2021!
A business and technology magazine based in Georgia, Atlanta, offering all reliable news and information from the industry straight to business leaders and professionals, has published an article : The Future of Healthcare: Revolutionizing Treatment for Any Disease with Stem Cell-based Cell Therapy.
See full article here
January 4, 2021
Kadimastem's report last year was rated the number 2 story on its "Top 10 ALS Stories of 2020" in ALS News Today
ALS News Today published an article by Marta Figueiredo in which she highlights the top ten most read articles on its website for 2020. Kadimastem's announcement on its completion of Cohort B and its preliminary efficacy results was rated second most read article of the year. We are grateful that our information is reaching the public and we will continue to update on out product results and progress. We have published 6 month follow up results of the second Cohort in December of 2020.
January 05, 2020
Kadimastem kicks off 2020 with good news
The Jerusalem Post article by Maayan Jaffe-Hoffman illustrates our current clinical trial with AstroRx® for the treatment of ALS and its abilities to replace functioning of damages cells using allogenic "off the shelf" stem cells. Click here for the full article
November 14, 2019
NoCamels writes about Kadimastem's cutting edge technology that stands out!
NoCamels article by Simona Shemer writes about Israeli companies that are driving innovation in diabetes care and treatment, she writes about Kadimastem and our "off the shelf" product IsletRx in pre-clinical trials for the treatment of Type 1 Diabetes. Click here for the full article.
May 5th, 2021
Kfir Molakandov PhD, head of Kadimastem’s diabetes cell therapy program was interviewed by Pharmaphorum on the topics near and dear to us at Kadimastem.
The title of the article written by Catherine Longworth is Tackling diabetes & ALS with cell therapy! Kadimastem wants to thank Catherine for her time and interest in our cell therapy company and the important work we are doing here. "As the head of diabetes research at Israeli cell therapy company Kadimastem, Molakandov believes they could have the next major diabetes therapy. The Tel-Aviv listed company is leading research and development of a cell therapy comprising functional pancreatic islet cells."
October 20, 2020
Kadimastem is proud to participate in the 9th Annual Friends4ALS Run on October 22nd – this year virtual
Join Kadimastem in supporting the Israel ALS Association which works hard to help improve the quality of life of ALS patients, support them and their families, and fund medical research to find a cure for this insidious disease.
Watch our short clip in support of IsrALS. We are ready! How about you?
January 14, 2017
Dont miss Arik Hasson, PhD, Exec. VP, of R&D present at the 7th international Stem Cell Meeting
Arik is Present Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv, Israel. Previously announced interim results demonstrated reduced disease progression in the first 3 months post-treatment period with AstroRx®. Click here for a link to the Meeting Site.
May 5th, 2021
@NBCLX on NBC hosted Michal Izrael PhD. on the 1st Monday of May to raise awareness for ALS on ALS Awareness Month.
May is ALS awareness month and Kadimastem is helping to bring awareness to as many as it can. Jobeth Devera interviewed our very own Michal Izrael PhD on the topic to share some important facts. Michal presented information on the global impact ALS has, and how we can all help. We want to thank Jobeth and @NBCLX for hosting Kadimastem and shedding light on the work we are doing to try and bring some hope to those suffering and in need of treatment for ALS and other neurological diseases.
August 05, 2020
See what ALS News Today has to say about our AstroRx® Product
The ALS News Today published a very positive article written by Inês Martins, PhD who states: "A pooled analysis of all 10 patients included in the trial showed that AstroRx® reduced the disease progression rate by 53%" Read this informative article on our latest published findings from Interim of Cohort B in our phase 1/2a clinical trial on ALS patients. Click here to read the article.
November 21, 2019
Catch us presenting at the Stem Cell Community Day 2019: Bringing the global stem cell research community together on November 21 in Portugal
Kadimastem was pleased to be part of the amazing stem cell Community leading the path to innovative promising treatments. Using DASBox, Eppendorff. Click here for event details.
October 03, 2019
The Times of Israel writes about our clinical trial for ALS
The times of Israel article by Shoshanna Solomon writes that Israeli company Kadimastem says interim results of first patient group indicate new drug ‘managed to significantly slow down disease progression’. Click here for the full article.